Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb22841 Monotherapy and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT03849469Phase 1Completed
- Sponsor
- Xencor
- Start
- May 2019
- Primary completion
- Feb 2023
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bavunalimab in solid tumor (advanced stage), melanoma, non-small cell lung carcinoma (NSCLC) and 12 more (2 arms), sponsored by Xencor. Primary endpoint: Safety and tolerability profile assessed by rates of treatment-related adverse events at 56 days. Started May 2019; status: completed.
02
Drugs
bavunalimab
03
Conditions
solid tumor (advanced stage)melanomanon-small cell lung carcinoma (NSCLC)renal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03849469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03849469.